<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381079</url>
  </required_header>
  <id_info>
    <org_study_id>TRECKY2017-049</org_study_id>
    <nct_id>NCT03381079</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Posterior Scleral Reinforcement on Controlling Myopia in Adults With High Myopia</brief_title>
  <official_title>Posterior Scleral Reinforcement for Adults With High Myopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of posterior scleral reinforcement on
      controlling myopia progression, including change in refraction, axial elongation as well as
      sight-threatening complications, in adults with high myopia. Half the adults will receive
      posterior scleral reinforcement, while the other half will receive no surgerical treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cycloplegic autorefraction</measure>
    <time_frame>2 years</time_frame>
    <description>Level of myopia and myopia progression as assessed by autorefraction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Axial length</measure>
    <time_frame>2 years</time_frame>
    <description>Longth of the eyeball as assessed by IOL Master or Lenstar</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Bleeding, inflammation or retinal detachment as assessed by B scan, slitlamp, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>2 years</time_frame>
    <description>An index for visual function measured by visual acuity chart</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>High Myopia</condition>
  <condition>Posterior Scleral Reinforcement</condition>
  <condition>Adults</condition>
  <condition>Axial Elongation</condition>
  <condition>Myopia Progression</condition>
  <arm_group>
    <arm_group_label>Surgical group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, the adults with high myopia will be given posterior scleral reinforcement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In this arm, the adults with high myopia will not be given any surgical treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Posterior scleral reinforcement</intervention_name>
    <description>Posterior scleral reinforcement (pPSR) is a procedure applied with autologous or biological material or synthetic materials reinforcing pole of the sclera after eyeball, in order to prevent or alleviate myopic development.</description>
    <arm_group_label>Surgical group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cycloplegic spherical equivalent less than -6.0 D

          -  Myopia progression greater than 1.0 D per year

          -  Normal IOP, no strabismus or any other ocular pathological changes

          -  no any other ocular or systematic diseases that may affect refractive development

        Exclusion Criteria:

          -  Currently or history using other interventions to control myopia progression
             (acupuncture, drugs, contact lens, ear needles and so on)

          -  Unable to cooperate with the ocular examination,questionnaire survey,or
             orthokeratology wearing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ningli Wang, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Tongren Eye Center, Beijing Tongren Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shi-Ming Li, PhD</last_name>
    <phone>+86-10-58269920</phone>
    <email>lishiming81@163.com</email>
  </overall_contact>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2017</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tongren Hospital</investigator_affiliation>
    <investigator_full_name>Shi-Ming Li</investigator_full_name>
    <investigator_title>Vice director of Ophthalmology clinical research center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

